Cytokinetics, Incorporated Stock News

Cytokinetics, Incorporated (NASDAQ:CYTK ) Citi's Biopharma Back to School Conference September 2, 2025 2:30 PM EDT Company Participants Robert I. Blum - CEO, President & Director Fady Malik - Executive Vice President of Research & Development Sung Lee - EVP & CFO Isaac Ciechanover - EVP of Corporate Development & Chief Business Officer Conference Call Participants David Lebowitz - Citigroup Inc...

MAPLE-HCM establishes Cytokinetics, Incorporated's aficamten as superior to metoprolol in obstructive HCM, reframing it as a potential first-line, best-in-class therapy. Commercial potential is significant, with U.S. peak sales scenarios ranging from ~$1.2B–$3.5B (net) depending on adoption, and higher if global and non-obstructive HCM are included. Differentiation vs. Camzyos (mavacamten) lies...

Cytokinetics, Incorporated -Exploring The Changing Treatment Paradigm Transcript Company Participants Diane Weiser - Senior Vice President of Corporate Affairs Fady Malik - Executive Vice President of Research & Development Daniel Jacoby Robert I. Blum - CEO, President & Director Conference Call Participants Pablo García-Pavia - Head, Heart Failure and Inherited Cardiac Diseases Unit, Hospital ...

Trial results for aficamten were presented to cardiologists over the weekend. One analyst said the drug could be “best-in-class therapy.

Additional Data from MAPLE-HCM Shows Aficamten  Improves Cardiac Structure and Function Compared to Metoprolol;  Simultaneous Publication in the Journal of the American College of Cardiology

Cytokinetics' experimental drug improved symptoms such as shortness of breath and chest pain better than a standard-of-care treatment in patients with a type of heart condition, detailed late-stage study data on Sunday showed.

Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers.

Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol Primary Endpoint Result Consistent Across All Prespecified Subgroups Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that primary res...